Kancera’s Fractaline Blockers May Fight Ovarian Cancer
Potential To Disrupt Cancer Cells' Resistance To Chemotherapy
Kancera AB’s fractalkine blockers have the potential to stop cancer cells acquiring resistance to chemotherapy and so offer potential to improve treatment for some advanced cancers, the Swedish biotech’s CEO tells Scrip.
You may also be interested in...
Russian sovereign wealth fund and Sputnik V vaccine producer RDIF has teamed up with the country’s biggest bank to fund ‘home-grown’ tech and science-intensive start-ups.
AstraZeneca's partner FibroGen stunned investors and regulators by announcing that previously disclosed cardiovascular safety data for CKD candidate roxadustat included changes made post hoc, rather than as pre-specified with the US FDA.
Q2 promises to be ‘transformational’ for AbiVax, propelled by key readouts for investigational anti-inflammatory, ABX464, and cancer agent, ABX196, but more funds will be needed by year end.